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Abstract
Aim
Our study aimed to find a correlation between low absolute lymphocyte count and COVID-19-related
mortality.
Methods
This study followed a retrospective observational cohort design to analyze the data of patients who
presented with symptoms and signs of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), at
the Conquest Hospital and Eastbourne District General Hospital in East Sussex, United Kingdom, between
February 10, 2020 and May 1, 2020, retrospectively. Survival and mortality for the first 30 days and
comorbidities were analyzed for all patients who were tested for COVID-19 irrespective of swab results and
had blood lymphocyte levels taken at the time of their visit to the ED and their data were analyzed for
statistical significance.
Results
A total of 1226 patients had SARS-CoV-2 RNA identification swabs taken between February 10, 2020 and
May 1, 2020. A cohort of 742 patients of these patients tested for COVID-19 also had blood lymphocyte
levels measured.
Overall, the lymphocyte count did not differ significantly between patients suspected to have COVID-19
infection with either positive or negative COVID-19 swab results.
The lymphocyte count, however, was significantly lower in those who died from COVID-19 (p < 0.001) but
when comorbidities were analyzed, we found an association between an increased number of comorbidities
and a significantly decreased lymphocyte count.
Conclusion
Once adjusted for comorbidities, the lymphocyte count had no association with COVID-19 infection and
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Introduction
The 21st century has witnessed a global pandemic of the COVID-19 phenomenon, that has wreaked havoc
worldwide issuing lockdowns, panic, and disaster. It is an illness that mainly affects the respiratory system
and is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. Information about
the prognostic markers is limited. Lymphopenia is defined as a lymphocyte count level less than 1.5 x10^9/l,
and several studies suggest an association of COVID-19 with lymphopenia [1,2]. Other studies have focused
on lymphocyte count mainly in the ICU during acute admission [3]. However, there is minimal information
available about the level of lymphopenia or lymphocyte count that is strongly associated with increased
mortality due to COVID-19. The role of comorbidity and other confounding variables is not clear [4].
The majority of the first studies are based on the initial days of the pandemic originating in Wuhan, China
[1,2,5]. Soon with the global pandemic, there were studies done highlighting the global implications of the
pandemic [3,6,7]. An additional global challenge for clinicians in an acute care setting is the reported studies
suggesting 70% sensitivity of the COVID-19 swab test. Studies have reported a pre-test probability of 50%
and the post-test probability with a negative test found to be 23%. This suggests it would be far too high to
assume someone is not infected [6].
We analyzed a cohort of patients admitted to ED with query COVID-19 infection who had COVID-19 swabs
done and had blood lymphocyte count requested; irrespective of a stay in medical wards or the ICU, and
analyzed the overall mortality over 30 days, as well its association with comorbidities. To our knowledge,
this appears to be the first attempt to analyze the significance of associated comorbidities with various
lymphocyte levels and mortality.
Aim of the study
With succeeding waves of the pandemic, we aimed to further characterize the level of lymphocyte count,
which is an inexpensive, yet quickly available biomarker, and the risk of mortality with COVID-19, to add to
the work done in China [1,2], and the United States of America [3].
Materials And Methods
Methodology
This was a retrospective study approved by our local audit department (East Sussex Healthcare NHS Trust).
Data were collected from the electronic medical record system and analyzed. COVID-19 swab results were
obtained between February 10, 2020 and May 1, 2020, from the Department of Microbiology Laboratory, for
patients being tested at the Conquest Hospital and Eastbourne District General Hospital in East Sussex,
United Kingdom. All the relevant blood tests, comorbidities, hospital admissions, and other relevant
information were collected from hospital records. A total of 1226 patients had SARS-CoV-2 RNA
identification swabs taken between February 10, 2020 and May 1, 2020. A cohort of 742 patients also had a
blood test for lymphocyte count through a full blood count (FBC) also known as complete blood count (CBC).
Patients with negative swab results who had features consistent with a diagnosis of COVID-19 including
fever, diarrhea, cough, and chest X-ray infiltrates were classified as if COVID-19 positive and were defined
as "Treat as Positive" (TAP). This helped to eliminate the discrepancy associated with false-positive or false-
negative swab results [6]. 
All the patients who had positive COVID-19 swab results or who were TAP were managed as per NHS
England guidelines (publication approval reference: 001559) [7]. This study included only those patients who
had both swabs and blood lymphocyte levels tested, including those who were admitted and treated or
discharged from the ED. Patients who had swabs taken but did not have blood lymphocyte levels taken were
excluded. Comorbidities of patients in the above-mentioned groups were collected from electronic records
and analyzed.
Statistical Analyses
The categorical variables were expressed in terms of frequency and percentages and were compared using
the chi-square test or Fisher’s exact test. Continuous variables were described as mean (SD) or median
(interquartile range [IQR]) and were compared between groups using a two-sample t-test. Spearman
correlation was used for correlation assessment. Mortality was assessed using logistic regression models.
2021 Zafar et al. Cureus 13(7): e16554. DOI 10.7759/cureus.16554 2 of 12
Lymphocyte count was log-transformed and two severe outliers were removed to give a normal distribution
before inclusion in the models. Results are presented as the OR associated with a 20% increase in
lymphocyte count. An adjustment was made for patient characteristics and comorbidities by including them
as covariates. As the prevalence for some covariates was low, we used a penalized model (Firth logistic
regression) to deal with any possible bias due to sparse data [8]. We tested for a difference in effect with age
by fitting an interaction term using age as a continuous variable. A probability of obtaining results p-value <
0.05 was taken to be significant. Non-linearity was assessed using restricted cubic splines. All statistical
analysis was done using Stata version 16 (StataCorp, Texas).
Results
A total of 742 patients were tested for SARS-CoV-2 RNA with a swab test and had blood tests for lymphocyte
count. The median age was 72 years and the age range was 1-101 years.
Of those suspected to have COVID-19 clinically 112 patients (15.1%) were swab positive and 630 (84.9%)
patients were swab negative. Patients with swab-positive results were significantly more likely to be ever
smokers and to have comorbidities. Lymphocyte count did not differ significantly between swab-negative
and swab-positive patients (Table 1).
Variable Swab negative, N = 630 Swab positive, N = 112 Total P-value
Age, years 68.4 (19.7) 70.9 (17.6) 68.8 (19.4) 0.21
Sex, % male (N) 47.9% (302) 56.3% (63) 49.2% (365) 0.11
Ever smoker, % (N) 3.9% (24) 16.5% (18) 5.8% (42) <0.001
CXR infiltrates, % (N) 34.1% (215) 56.3% (63) 37.5% (278) <0.001
Comorbidities     
Diabetes, % (N) Type 1/Type 2 0.5% (3) 2.6% (16) 0.9% (1) 5.5% (6) 0.6% (4) 3.1% (22) 0.48 0.13
Diarrhea, % (N) 9.1% (57) 29.5% (33) 12.1% (90) <0.001
IHD, % (N) 17.2% (105) 29.4% (32) 19.1% (137) 0.003
Asthma/COPD/ILD % (N) 10.3% (63) 21.1% (23) 12.0% (86) 0.001
Hypertension, % (N) 10.3% (63) 19.3% (21) 11.7% (84) 0.007
Dementia, % (N) 8.4% (51) 20.2% (22) 10.2% (73) <0.001
Frailty, % (N) 12.0% (73) 22.9% (25) 13.6% (98) 0.002
ALD-CLD, % (N) 1.5% (9) 1.8% (2) 1.5% (11) 0.68
Malignancy, % (N) 2.6% (16) 14.7% (16) 4.5% (32) <0.001
PE, % (N) 1.0% (6) 3.7% (4) 1.4% (10) 0.051
Lymphocyte count, 109/ L* 1.12 [0.71-1.68] 1.04 [0.63-1.5] 1.12 [0.71-1.66] 0.27
Lymphocyte count < 1.5x109/ L 69.8% (440) 75.0% (84) 70.6% (524) 0.27
TABLE 1: Patient characteristics and comorbidities.
ALD: Alcohol liver disease; CLD: Chronic liver disease; COPD: Chronic obstructive pulmonary disease; CXR: Chest X-ray; DMx1: Diabetes mellitus
type 1; DMx2: Diabetes mellitus type 2; Frailty: Dalhousie Frailty (Rockwood) score of 4 or more classified as frail; IHD: Ischemic heart disease; ILD:
Interstitial lung disease; IQR: Interquartile range; N: Number of cases; PE: Pulmonary embolism.
Of the 742 patients, 584 (78.7%) were alive after 30 days, while 158 (21.3%) had died. Patients who died were
significantly older (79 vs. 66 years) and more likely to be male (58% vs. 47%), smokers (26% vs. 0.4%), and to
have co-morbidities (Table 1). Mortality rates were 33.9% (38/112) in swab-positive patients and 19.1%
(120/630) in swab-negative patients. Swab-positive patients who died were more likely to be smokers and
had higher rates of comorbidity (Table 1). Lymphocyte counts were significantly lower in patients who died
(1.22 vs. 0.76) in the total population and non-significantly lower in the swab-positive population (Table 2).
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  All patients Positive patients
Variable  Alive Deceased P-value Alive Deceased P-value
N  N = 584 N = 158  N = 74 N = 38  
Age Years 66.1 (20.0) 78.9 (12.1) <0.001 66.4 (18.6) 79.7 (11.1) <0.001
Male Sex % (N) 46.8% (273) 58.2% (92) 0.01 52.7% (39) 63.2% (24) 0.29
Ever smoker % (N) 0.4% (2) 25.6% (40) <0.001 0% (0) 48.7% (18) <0.001
CXR infiltrates % (N) 30.5% (178) 63.3% (100) <0.001 52.7% (39) 63.2% (24) 0.29
Comorbidities        
DMx1 % (N) 0.4% (2) 1.3% (2) 0.21 1.4% (1) 0 (0) 1.00
DMx2 % (N) 0.2% (1) 13.6% (21) <0.001 0% (0) 16.2% (6) 0.001
Diarrhea % (N) 12.2% (71) 12.0% (19) 0.96 25.7% (19) 36.8% (14) 0.22
IHD % (N) 6.2% (35) 65.4% (102) <0.001 4.2% (3) 78.4% (29) <0.001
Asthma/COPD/ILD % (N) 2.8% (16) 44.9% (70) <0.001 1.4% (1) 59.5% (22) <0.001
Hypertension % (N) 4.6% (26) 37.2% (58) <0.001 2.8% (2) 51.4% (19) <0.001
Dementia % (N) 4.1% (23) 32.1% (50) <0.001 5.6% (4) 48.7% (18) <0.001
Frailty % (N) 4.3% (24) 47.4% (74) <0.001 2.8% (2) 62.2% (23) <0.001
ALD-CLD % (N) 0 (0%) 7.1% (11) <0.001 0% (0) 5.4% (2) 0.11
Malignancy % (N) 0 (0%) 20.5% (32) <0.001 0% (0) 43.2% (16) <0.001
PE % (N) 0 (0%) 6.5% (10) <0.001 0% (0) 10.8% (4) 0.012
Lymphocyte count* 109/L 1.22 [0.76-1.76] 0.76 [0.52-1.09] <0.001 1.17 [0.72-1.63] 0.76 [0.58-1.25] 0.057
Lymphocyte count <1.5x109/L % (N) 66.1% (386) 87.3% (138) <0.001 71.6% (53) 81.6% (31) 0.36
Covid swab positive % (N) 12.7% (74) 24.1% (38) <0.001 - - -
TABLE 2: Patient characteristics and comorbidities by mortality.
ALD: Alcohol liver disease; CLD: Chronic liver disease; COPD: Chronic obstructive pulmonary disease; CXR: Chest X-ray; DMx1: Diabetes mellitus
type 1; DMx2: Diabetes mellitus type 2; Frailty: Dalhousie Frailty (Rockwood) score of 4 or more classified as frail; IHD: Ischemic heart disease; ILD:
Interstitial lung disease; IQR: Interquartile range; N: Number of cases; PE: Pulmonary embolism.
We analyzed confounding variables that may have contributed to this finding. Lymphocyte count decreased
with age (Spearman's Rho = -0.38; p < 0.001) and was lower in men than women (Table 3). Lymphocyte count
was also significantly decreased in those with all comorbidities except in those patients with diarrhea or type
1 diabetes (Table 3). After adjustment for comorbidities, however, there was no significant association of
lymphocyte count with mortality in the total population or in swab-positive patients (Table 4).
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 No Yes P-value
Male sex 1.15 (0.62-1.78) 377 1.06 (0.62-1.54) N = 365 0.03
Diarrhea 1.12 [0.70-1.67] N = 652 1.12 [0.73-1.65] N = 90 0.63
IHD 1.19 [0.73-1.75] N = 582 0.76 [0.47-1.09] N =1 37 <0.001
Asthma/COPD/ILD 1.18 [0.72-1.75] N = 633 0.71 [0.49-0.90] N = 86 <0.001
Hypertension 1.17 [0.71-1.74] N = 635 0.76 [0.59-1.05] N = 84 <0.001
Dementia 1.16 [0.71-1.70] N = 646 0.76 [0.59-1.06] N = 73 <0.001
Frailty 1.18 [0.71-1.74] N = 621 0.77 [0.59-1.08] N = 98 <0.001
Ever smoker 1.15 [0.71-1.7] N = 677 0.75 [0.60-0.88] N = 42 <0.001
ALD/CLD 1.12 [0.70-1.69] N = 708 0.78 [0.59-0.87] N = 11 0.03
Malignancy 1.13 [0.70-1.69] N = 687 0.76 [0.62-0.91] N = 32 0.003
PE 1.12 [0.7-1.68] N = 708 0.67 [0.58-0.88] N = 10 0.02
DMx2 1.12 [0.71-1.69] N = 696 0.76 [0.43-0.92] N = 22 0.01
DMx1 1.11 [0.69-1.66] N = 714 1.12 [0.78-1.66] N = 4 0.85
TABLE 3: Median lymphocyte count [IQR] by sex and comorbidities.
ALD: Alcohol liver disease; CLD: Chronic liver disease; COPD: Chronic obstructive pulmonary disease; CXR: Chest X-ray; DMx1: Diabetes mellitus
type 1; DMx2: Diabetes mellitus type 2; Frailty: Dalhousie Frailty (Rockwood) score of 4 or more classified as frail; IHD: Ischemic heart disease; ILD:
Interstitial lung disease; IQR: Interquartile range; N: Number of cases; PE: Pulmonary embolism.
                                                              All patients                                                     Swab-positive patients
 OR (95% CI) P value OR (95% CI) P value
Unadjusted 0.84 (0.79-0.88) <0.0001 0.94 (0.85-1.05) 0.31
Model 2 0.89 (0.84-0.95) <0.0001 1.05 (0.90-1.22) 0.54
Model 3 0.96 (0.88-1.04) 0.29 1.03 (0.81-1.32) 0.79
TABLE 4: Firth logistic regression models for mortality by lymphocyte count.
Model 2: Adjusted for age, sex, ever smoking, and swab positivity.
Model 3: Adjusted for age, sex, ever smoking, swab positivity, and comorbidities.
There was significant evidence of non-linearity (p < 0.001) in the unadjusted model, with risk no longer
declining once lymphocyte levels increased above 1.6 x 109/L (Figure 1). After adjustment for comorbidity,
there was no significant non-linearity (p = 0.13, Figure 2).
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FIGURE 1: Restricted cubic splines for the non-linear association of
lymphocyte count with mortality; unadjusted.
Log: Logarithm
Loge: Exponent of the log
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FIGURE 2: Restricted cubic splines for the non-linear association of
lymphocyte count with mortality; adjusted for age, sex, swab positivity,
and comorbidity.
Log: Logarithm
Loge: Exponent of the log
We also examined whether the effect of lymphocyte count differed by age (Table 5), and found no evidence
of interaction (p = 0.09). Lasso model was used to analyze mortality in swab-positive patients (Table 6) and
overall mortality (Table 7). Finally, this data was analyzed for the association of lymphocyte count and
without lymphocyte count for any relevance with the area under a receiver operating characteristic (ROC)
curve (Figure 3).
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 All patients Positive patients
Age, years Alive Deceased Alive Deceased
N N = 584 N = 158 N = 74 N = 38
<58 years 1.63 [1.12-2.04] 179 0.76 [0.56-1.46] 7 1.36 [1.03-1.87] 28 0.56 [0.56-0.56] 1
58-72 years 1.32 [0.84-1.76] 154 0.74 [0.54-1.15] 35 0.99 [0.66-1.40] 20 1.15 [0.73-4.02] 9
73-84 years 1.07 [0.71-1.33] 132 0.72 [0.42-1.05] 58 0.71 [0.47-1.16] 8 0.75 [0.54-0.78] 14
>=85 years 0.87 [0.55-1.28] 119 0.85 [0.59-1.08] 58 1.05 [0.62-1.37] 18 0.93 [0.59-1.28] 14
P-value (interaction) P = 0.09 P = 0.66
TABLE 5: Lymphocyte count by mortality and quartile of age: median [IQR] N.






ROC area (95% CI) 0.981 (0.962-1.00)
TABLE 6: Lasso models for predicting death in swab-positive patients. Lymphocyte does not
contribute to the predictive model for swab-positive patients.
COPD: Chronic obstructive pulmonary disease; Frailty: Dalhousie frailty (Rockwood) score of 4 or more classified as frail; IHD: Ischemic heart
disease; ILD: Interstitial lung disease; ROC: The area under a receiver operating characteristic curve. 
2021 Zafar et al. Cureus 13(7): e16554. DOI 10.7759/cureus.16554 8 of 12
 Model 1 Model 2
Variable Model coefficients Model coefficients
Age 0.027 0.022
Male sex 0.528 0.429








ROC area (95% CI) 0.944 (0.926-0.962) 0.943 (0.924-0.961)
TABLE 7: Lasso models for predicting death – all patients.
COPD: Chronic obstructive pulmonary disease; Frailty: Dalhousie Frailty (Rockwood) score of 4 or more classified as frail; IHD: Ischemic heart
disease; ILD: Interstitial lung disease; ROC: Area under a receiver operating characteristic curve.
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FIGURE 3: Area under the ROC curve for predictive models for mortality
in all patients. Model 1 without lymphocyte count and Model 2 with
lymphocyte count added.
ROC: Receiver operating characteristic curve.
Discussion
COVID-19 is a highly infectious disease with significant morbidity and mortality. Although there is no
relative scarcity of information towards awareness for the severity of the disease, there remains a lot of need
to do more to improve the overall outcome. Multiple biomarkers have been considered towards its diagnosis
along with COVID-19 swabs, which have been noted as having low sensitivity [9]. The utilization of
lymphocyte count and in particular lymphopenia has drawn great attention for practice towards managing
patients suspected to have COVID-19 [1,2]. Other studies have focused on the association in patients
admitted to the ICU [3] or the odds of getting admitted to the ICU with lymphopenia [10]. There is a trend
towards a higher risk of acquiring infection as well as increased severity with COVID-19 in absolute
lymphopenia range. The presence of lymphopenia is associated with a threefold increased risk of severe
COVID-19 [10].
Others have studied the association of lymphocyte and neutrophil count and COVID-19 [11]. Yun H et al.
reported that lymphocyte counts were markedly low in COVID-19-positive patients [12]. Similarly, a recently
published study from Wuhan, China, showed that the lymphocyte count was considerably lower
among patients who succumbed to COVID-19 compared to those who survived [13]. On the contrary, our
study shows no relationship between lymphopenia and having COVID-19.
Furthermore, in COVID-19 patients, mortality rates did not change with the level of lymphocyte count. Any
observed association within the total population was explained by the increased prevalence of comorbidities
among those with lower lymphocyte count. Interestingly, it has long been determined that the process of
lymphopoiesis is noticeably disrupted in the aging population due to an aging immune system. Since our
study cohort includes patients of all age groups rather than merely the elderly, it is possible that we did not
see any relationship with lymphopenia [14,15]. Although even in older patients we found no association of
lymphocyte count and COVID-19 infection or mortality with COVID-19. Based on the statistical analysis of
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comorbidity data, it appears that comorbidities contribute more towards mortality than lymphocyte count.
Our study does have limitations, including no standardization for ethnicity and inclusion of only acute
presentations. Patients who were referred to our hospitals for swab testing but had no lymphocyte count
performed were excluded. Patients who had a COVID-19 swab test but were not admitted to the hospital
were also excluded as their blood lymphocyte levels were not available.
As our analysis is conditional on patients having a test, we cannot rule out selection bias in our results.
However, the observed associations with testing positive and mortality were all in the expected direction. As
the world attempts to grasp the COVID-19 phenomenon, we realize a number of observations have been
made towards associations [16] and emerging evidence of side-effects of varying COVID-19 vaccines [17]. We
hope our study offers the missing piece of the puzzle towards comorbidity associations.
Conclusions
In conclusion, we did not find a strong relationship between lymphocyte levels and COVID-19-related
mortality, especially the mortality caused by the infection, with age, gender, swab outcomes, and
comorbidities adjusted. Additionally, there was no association with testing positive, as swab-positive
patients did not show a significant reduction in lymphocyte compared to swab-negative patients. The most
vulnerable group of the population for COVID-19, the aging population, as well as other age groups, have
factors aside from lymphocyte levels, which may include comorbidities such as diabetes mellitus type 1 and
2; various cancers, and chronic heart failure. These comorbidities may contribute to more association with
acquiring infection and increased mortality with COVID-19. Overall, this study brings to light the
misconception of one of the more widely embraced myths that low lymphocyte count is a major
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